8,749 Shares in Medpace Holdings, Inc. $MEDP Bought by Magnetar Financial LLC

Key Points

• Magnetar Financial LLC acquired a stake in Medpace Holdings, purchasing 8,749 shares valued at approximately $2.67 million in the first quarter of the year.
• Multiple institutional investors have increased their investments in Medpace, contributing to a total institutional ownership of 77.98%.
• Wall Street analysts have raised their price targets for Medpace, with estimates ranging from $366.00 to $510.00, while the stock has garnered mixed ratings across the analyst community.

Magnetar Financial LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,749 shares of the company's stock, valued at approximately $2,666,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sone Capital Management LLC bought a new position in shares of Medpace during the 4th quarter valued at $1,318,000. GAMMA Investing LLC raised its holdings in shares of Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after purchasing an additional 83 shares in the last quarter. Fundsmith LLP bought a new position in shares of Medpace during the 4th quarter valued at $42,372,000. Hsbc Holdings PLC raised its holdings in shares of Medpace by 157.5% during the 1st quarter. Hsbc Holdings PLC now owns 4,364 shares of the company's stock valued at $1,296,000 after purchasing an additional 2,669 shares in the last quarter. Finally, Park Avenue Securities LLC raised its holdings in shares of Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 151,266 shares of company stock valued at $69,311,427 in the last three months. 20.30% of the stock is currently owned by corporate insiders.

Medpace Stock Down 0.9%

NASDAQ:MEDP traded down $4.31 on Thursday, reaching $476.92. The stock had a trading volume of 88,559 shares, compared to its average volume of 445,317. The company has a market capitalization of $13.40 billion, a P/E ratio of 35.39, a price-to-earnings-growth ratio of 2.99 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The stock has a fifty day moving average price of $405.65 and a 200-day moving average price of $342.20.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MEDP. TD Cowen restated a "sell" rating and set a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Barclays lifted their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Robert W. Baird lifted their target price on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and lifted their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $412.73.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.